Mutagenic Impurities: Precompetitive/Competitive Collaborative and Data Sharing Initiatives

Precompetitive and competitive collaborations have flourished during the development of the ICH M7 guidelines (mutagenic impurities). The majority of these interactions are “honest broker” type arrangements, where an autonomous, independent third party is tasked with coordinating the activities of the consortium. Sometimes, more than one “honest broker” can be involved in the activity. Lhasa has been at the center of many of these collaborative initiatives; i.e., Derek Nexus Pharmaceutical Intermediates, Excipients, Zeneth, Mirabilis. The Product Quality Research Institute (PQRI) coordinated activities allowing a mechanistic understanding of the reaction mechanism for the formation of sulfonate esters, which after the Viracept withdrawal had been at the forefront of regulatory thinking. Other “not for profit” organizations that have played a role in the advancement of the greater understanding of mutagenic impurities include the various trade organizations, i.e., the Pharmaceutical Research and Manufactur...

[1]  D. Elder,et al.  An Approach to Control Strategies for Sulfonate Ester Formation in Pharmaceutical Manufacturing Based on Recent Scientific Understanding , 2012 .

[2]  David Q. Liu,et al.  A practical derivatization LC/MS approach for determination of trace level alkyl sulfonates and dialkyl sulfates genotoxic impurities in drug substances. , 2008, Journal of pharmaceutical and biomedical analysis.

[3]  David S. Jones The Journal of Pharmacy and Pharmacology 2008 , 2009 .

[4]  Jared L. Anderson,et al.  Determination of trace level genotoxic impurities in small molecule drug substances using conventional headspace gas chromatography with contemporary ionic liquid diluents and electron capture detection. , 2014, Journal of chromatography. A.

[5]  Heather Scott,et al.  Ames positive boronic acids are not all eukaryotic genotoxins. , 2015, Mutation research. Genetic toxicology and environmental mutagenesis.

[6]  William F. Kiesman,et al.  Case Studies in the Applicability of Drug Substance Design Spaces Developed on the Laboratory Scale to Commercial Manufacturing , 2015 .

[7]  Patrick Sandra,et al.  A Detailed Study of Sulfonate Ester Formation and Solvolysis Reaction Rates and Application toward Establishing Sulfonate Ester Control in Pharmaceutical Manufacturing Processes , 2010 .

[8]  D. Elder,et al.  Analytical approaches for the detection of epoxides and hydroperoxides in active pharmaceutical ingredients, drug products and herbals. , 2010, Journal of pharmaceutical and biomedical analysis.

[9]  Karen M. Alsante,et al.  In silico prediction of pharmaceutical degradation pathways: a benchmarking study. , 2014, Molecular pharmaceutics.

[10]  V. Ciaravino,et al.  An assessment of the genetic toxicology of novel boron‐containing therapeutic agents , 2013, Environmental and molecular mutagenesis.

[11]  H. Niederländer,et al.  A new derivatization reagent for LC-MS/MS screening of potential genotoxic alkylation compounds. , 2013, Journal of pharmaceutical and biomedical analysis.

[12]  Achille Cappiello,et al.  A new liquid chromatography-mass spectrometry approach for generic screening and quantitation of potential genotoxic alkylation compounds without derivatization. , 2012, Journal of chromatography. A.

[13]  D. Elder,et al.  Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs). , 2008, Journal of pharmaceutical and biomedical analysis.

[14]  Nigel Greene,et al.  In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry survey. , 2012, Regulatory toxicology and pharmacology : RTP.

[15]  David H Phillips,et al.  Boronic acids-a novel class of bacterial mutagen. , 2011, Mutation research.

[16]  Andrew Teasdale,et al.  A Tool for the Semiquantitative Assessment of Potentially Genotoxic Impurity (PGI) Carryover into API Using Physicochemical Parameters and Process Conditions , 2010 .

[17]  D. Elder,et al.  Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs). , 2008, Journal of pharmaceutical and biomedical analysis.

[18]  Scott Boyer,et al.  Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. , 2013, Regulatory toxicology and pharmacology : RTP.

[19]  J. Woodcock Precompetitive Research: A New Prescription for Drug Development? , 2010, Clinical pharmacology and therapeutics.

[20]  Andrei Medvedovici,et al.  Assay at low ppm level of dimethyl sulfate in starting materials for API synthesis using derivatization in ionic liquid media and LC-MS. , 2013, Journal of pharmaceutical and biomedical analysis.

[21]  David Q. Liu,et al.  A generic approach for the determination of trace hydrazine in drug substances using in situ derivatization-headspace GC-MS. , 2009, Journal of pharmaceutical and biomedical analysis.

[22]  Andrew Teasdale,et al.  Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control , 2013 .

[23]  D. Elder,et al.  Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products. , 2011, Journal of pharmaceutical and biomedical analysis.

[24]  David Q. Liu,et al.  Recent advances in trace analysis of pharmaceutical genotoxic impurities. , 2010, Journal of pharmaceutical and biomedical analysis.

[25]  Feng Zheng,et al.  Rapid and simultaneous determination of sulfonate ester genotoxic impurities in drug substance by liquid chromatography coupled to tandem mass spectrometry: comparison of different ionization modes. , 2014, Journal of chromatography. A.

[26]  N V V S S Raman,et al.  Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective. , 2011, Journal of pharmaceutical and biomedical analysis.

[27]  G. Sluggett,et al.  Determination and control of TEMPO, a potentially genotoxic free radical reagent used in the synthesis of filibuvir. , 2012, Journal of pharmaceutical and biomedical analysis.

[28]  Patrick Sandra,et al.  The utility of sulfonate salts in drug development. , 2010, Journal of pharmaceutical sciences.

[29]  Christopher J. Welch,et al.  Precompetitive Collaboration on Enabling Technologies for the Pharmaceutical Industry , 2014 .

[30]  Patrick Sandra,et al.  Mechanism and Processing Parameters Affecting the Formation of Methyl Methanesulfonate from Methanol and Methanesulfonic Acid: An Illustrative Example for Sulfonate Ester Impurity Formation , 2009 .

[31]  M. A. Ott,et al.  An expert system to predict the forced degradation of organic molecules. , 2013, Molecular pharmaceutics.

[32]  R. E. Boyle THE REACTION OF DIMETHYLSULFOXIDE AND 5-DIMETHYL AMINONAPHTHALENE-1- SULFONYL CHLORIDE , 1966 .

[33]  Thomas E. Exner,et al.  Can quantum-chemical NMR chemical shifts be used as criterion for force-field development , 2014, Journal of Cheminformatics.

[34]  P R Kakadiya,et al.  Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavir and Ritonavir Active pharmaceutical ingredients by LC/MS/MS using electrospray ionization. , 2011, Journal of pharmaceutical and biomedical analysis.

[35]  D. Elder,et al.  Drug substances presented as sulfonic acid salts: overview of utility, safety and regulation , 2009 .

[36]  Roman Szucs,et al.  A generic approach for the determination of residues of alkylating agents in active pharmaceutical ingredients by in situ derivatization-headspace-gas chromatography-mass spectrometry. , 2007, Journal of pharmaceutical and biomedical analysis.

[37]  Andrew Teasdale,et al.  Development and validation of an automated static headspace gas chromatography-mass spectrometry (SHS-GC-MS) method for monitoring the formation of ethyl methane sulfonate from ethanol and methane sulfonic acid. , 2008, Journal of pharmaceutical and biomedical analysis.

[38]  Samuel J. Webb,et al.  Self organising hypothesis networks: a new approach for representing and structuring SAR knowledge , 2014, Journal of Cheminformatics.

[39]  G. Szekely,et al.  Design of experiments as a tool for LC-MS/MS method development for the trace analysis of the potentially genotoxic 4-dimethylaminopyridine impurity in glucocorticoids. , 2012, Journal of pharmaceutical and biomedical analysis.

[40]  T. Singer,et al.  Comparative evaluation of in silico systems for ames test mutagenicity prediction: scope and limitations. , 2011, Chemical research in toxicology.

[41]  Carol A Marchant,et al.  In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic , 2008, Toxicology mechanisms and methods.